Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E336724-1mg | 1mg | In stock | $157.90 | |
E336724-5mg | 5mg | In stock | $711.90 | |
E336724-10mg | 10mg | In stock | $1,279.90 | |
E336724-25mg | 25mg | In stock | $2,879.90 | |
E336724-50mg | 50mg | In stock | $5,183.90 |
a metabolite of Estradiol
Synonyms | estra-1,3,5(10)-triene-3,15alpha,16alpha,17beta-tetrol | Drovelis (EMA); ; estetrol monohydrate + drospirenone | ESTETROL [WHO-DD] | (14beta,15alpha,16alpha,17alpha)-Estra-1,3,5(10)-Triene-3,15,16,17-Tetrol | GTPL11591 | WHO 10439 | AT27982 | CHEBI:14277 |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Estrogen receptor agonist |
Product Description | A metabolite of Estradiol that is an estrogenic steroid synthesized exclusively by the fetal liver during human pregnancy and reaches the maternal circulation through the placenta. |
ALogP | 1.5 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (8R,9S,13S,14S,15R,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,15,16,17-tetrol |
---|---|
INCHI | InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1 |
InChi Key | AJIPIJNNOJSSQC-NYLIRDPKSA-N |
Canonical SMILES | CC12CCC3C(C1C(C(C2O)O)O)CCC4=C3C=CC(=C4)O |
Isomeric SMILES | C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O |
PubChem CID | 27125 |
Molecular Weight | 304.38 |
CAS Registry No. | 15183-37-6 |
---|---|
PubChem CID | 27125 |
ChEMBL Ligand | CHEMBL1230314 |
DrugBank Ligand | DB12235 |
BindingDB Ligand | 158505 |
RCSB PDB Ligand | 4OH |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2214663 | Certificate of Analysis | Dec 08, 2022 | E336724 |
L2214965 | Certificate of Analysis | Dec 08, 2022 | E336724 |
L2215307 | Certificate of Analysis | Dec 08, 2022 | E336724 |
L2215308 | Certificate of Analysis | Dec 08, 2022 | E336724 |
L2215312 | Certificate of Analysis | Dec 08, 2022 | E336724 |
Solubility | Soluble in methanol, and acetone. |
---|---|
Refractive Index | n20D1.65 (Predicted) |
Boil Point(°C) | 491.94° C at 760 mmHg (Predicted) |
Melt Point(°C) | 233-236° C |
Pictogram(s) | GHS08 |
---|---|
Signal | Danger |
Hazard Statements | H351:Suspected of causing cancer H360:May damage fertility or the unborn child H362:May cause harm to breast-fed children |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P263:Avoid contact during pregnancy/while nursing. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
1. Coelingh Bennink HJ, Holinka CF, Diczfalusy E. (2008) Estetrol review: profile and potential clinical applications.. Climacteric, 11 Suppl 1 (13): (47-58). [PMID:18464023] [10.1021/op500134e] |
2. Visser M, Foidart JM, Coelingh Bennink HJ. (2008) In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism.. Climacteric, 11 Suppl 1 (13): (64-8). [PMID:18464025] [10.1021/op500134e] |
3. P K. (2021) Estetrol and the possibilities of its clinical use.. Ceska Gynekol, 86 (3): (217-221). [PMID:34167315] [10.1021/op500134e] |